Literature DB >> 619579

The comeback of hydralazine.

J Koch-Weser.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 619579     DOI: 10.1016/0002-8703(78)90391-5

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  7 in total

Review 1.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

Review 2.  Antihypertensive pharmacology.

Authors:  J G Gerber; C R Freed; A S Nies
Journal:  West J Med       Date:  1980-05

3.  Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.

Authors:  D D Shen; J P Hosler; R L Schroder; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

4.  Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man.

Authors:  V Facchini; J A Timbrell
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

5.  Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients.

Authors:  R Eggertsen; L Andrén; R Sivertsson; L Hansson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Hydralazine-induced lupus: is there a toxic metabolic pathway?

Authors:  J A Timbrell; V Facchini; S J Harland; R Mansilla-Tinoco
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients.

Authors:  J H Silas; F C Phillips; S Freestone; G T Tucker; L E Ramsay
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.